mannitol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
935 69-65-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • d-mannitol
  • mannitol
  • mannitol,d-
  • bronchitol
A diuretic and renal diagnostic aid related to sorbitol. It has little significant energy value as it is largely eliminated from the body before any metabolism can take place. It can be used to treat oliguria associated with kidney failure or other manifestations of inadequate renal function and has been used for determination of glomerular filtration rate. Mannitol is also commonly used as a research tool in cell biological studies, usually to control osmolarity.
  • Molecular weight: 182.17
  • Formula: C6H14O6
  • CLOGP: -2.05
  • LIPINSKI: 1
  • HAC: 6
  • HDO: 6
  • TPSA: 121.38
  • ALOGS: 0.10
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.80 g Inhal.powder

ADMET properties:

PropertyValueReference
BA (Bioavailability) 7 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.24 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.20 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 4.70 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 213 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -2.492 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.309 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.560 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 0.692 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 90.970 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 96.530 % High 1
herg hERG pIC50 3.502 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 0.920 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.228 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 85.930 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK2,PDK2,PDK4,PIK3CB,PIK3CD,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK 34
kinase-selectivity-class ACVRL1,AURKB,AXL,BMX,BRAF,CDK1,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK8,CDK9,CHUK,DYRK1A,EPHB4,IGF1R,INSR,IRAK1,IRAK3,IRAK4,KIT,MAP2K6,MAP3K14,MAP3K21,MAP3K7,PAK4,PDGFRB,PDK1,PIK3CB,PIK3CD,PIK3CG,PRKDC,SYK,TEK,TGFBR1,TYRO3,ZAP70 39
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.269 High 1
mh-clint Mouse hepatocyte intrinsic clearance 0.182 High 1
mppb Mouse plasma protein binding (% unbound) 97.890 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.316 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 96.500 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.671 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 96.880 % High 1
rppb Rat plasma protein binding (% unbound) 96.900 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 950.605 uM High 1

Approvals:

DateAgencyCompanyOrphan
June 8, 1964 FDA BAXTER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Renal injury 227.10 21.63 65 6469 10178 90611735
Fear 196.08 21.63 65 6469 16557 90605356
Renal impairment 184.34 21.63 107 6427 105314 90516599
Renal failure 131.99 21.63 94 6440 130913 90491000
Anhedonia 131.98 21.63 44 6490 11387 90610526
Emotional distress 117.85 21.63 56 6478 36606 90585307
Multiple organ dysfunction syndrome 115.72 21.63 68 6466 68268 90553645
Unevaluable event 115.63 21.63 63 6471 54785 90567128
Brain oedema 66.58 21.63 30 6504 17355 90604558
Chills 58.36 21.63 59 6475 131922 90489991
Injury 52.82 21.63 68 6466 197281 90424632
Stress 52.66 21.63 45 6489 81350 90540563
Anxiety 52.60 21.63 86 6448 309686 90312227
Chest discomfort 47.32 21.63 54 6480 138311 90483602
Cerebral haemorrhage 44.75 21.63 29 6505 34493 90587420
Hypokalaemia 42.86 21.63 50 6484 131066 90490847
Circulatory collapse 42.68 21.63 25 6509 24879 90597034
Coma 42.63 21.63 38 6496 72594 90549319
Rash erythematous 40.08 21.63 35 6499 65069 90556844
Fanconi syndrome 37.15 21.63 11 6523 1932 90619981
Brain death 36.74 21.63 13 6521 4008 90617905
Brain herniation 36.19 21.63 13 6521 4187 90617726
Maculopathy 34.39 21.63 11 6523 2495 90619418
Cardio-respiratory arrest 33.08 21.63 31 6503 63109 90558804
Blood creatinine increased 32.02 21.63 38 6496 101348 90520565
Propofol infusion syndrome 31.92 21.63 9 6525 1330 90620583
Haemodynamic instability 31.90 21.63 16 6518 11723 90610190
Cerebral venous sinus thrombosis 30.85 21.63 10 6524 2366 90619547
Hepatic function abnormal 30.75 21.63 26 6508 46262 90575651
Gastrointestinal bacterial infection 29.14 21.63 8 6526 1072 90620841
Hyperosmolar state 28.43 21.63 6 6528 263 90621650
Arthralgia 27.36 21.63 11 6523 778511 89843402
Hyperkalaemia 26.79 21.63 28 6506 64936 90556977
Hyponatraemia 26.67 21.63 40 6494 133498 90488415
Metabolic acidosis 26.63 21.63 26 6508 55650 90566263
Cardiac arrest 26.24 21.63 35 6499 104900 90517013
Disorientation 25.72 21.63 23 6511 44091 90577822
CSF volume decreased 25.61 21.63 3 6531 0 90621913
Acute kidney injury 25.48 21.63 65 6469 320322 90301591
Seizure 25.33 21.63 42 6492 152587 90469326
Posterior reversible encephalopathy syndrome 24.69 21.63 17 6517 22322 90599591
Clostridial sepsis 23.91 21.63 6 6528 567 90621346
Intracranial pressure increased 23.70 21.63 11 6523 6800 90615113
Parasitic encephalitis 23.67 21.63 4 6530 51 90621862
Cerebral toxoplasmosis 22.75 21.63 7 6527 1398 90620515
Urine output decreased 22.51 21.63 13 6521 12590 90609323
Aphasia 22.38 21.63 21 6513 42791 90579122
Drug intolerance 22.21 21.63 3 6531 447588 90174325

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Stress 321.45 21.09 194 14049 44018 42563074
Fear 275.10 21.09 112 14131 10853 42596239
Renal injury 249.67 21.09 108 14135 12172 42594920
Injury 241.00 21.09 127 14116 22189 42584903
Anhedonia 229.88 21.09 89 14154 7551 42599541
Multiple organ dysfunction syndrome 208.36 21.09 206 14037 96829 42510263
Emotional distress 206.81 21.09 103 14140 15990 42591102
Appendicolith 199.59 21.09 95 14148 13361 42593731
Blood phosphorus increased 187.51 21.09 89 14154 12436 42594656
Myasthenia gravis 186.10 21.09 96 14147 16041 42591051
Hyperphosphataemia 169.35 21.09 84 14159 12920 42594172
Unevaluable event 169.03 21.09 118 14125 34170 42572922
Appendicitis 164.08 21.09 96 14147 20517 42586575
Renal impairment 156.08 21.09 188 14055 110040 42497052
Hypophosphataemia 149.67 21.09 91 14152 20854 42586238
Ventricular fibrillation 149.24 21.09 104 14139 30019 42577073
Blood uric acid increased 130.60 21.09 75 14168 15472 42591620
Analgesic therapy 124.82 21.09 55 14188 6469 42600623
Neuralgia 121.10 21.09 86 14157 25561 42581531
Cardiogenic shock 120.72 21.09 98 14145 35542 42571550
Drug therapy 119.52 21.09 53 14190 6327 42600765
Sleep disorder therapy 118.74 21.09 54 14189 6840 42600252
Hyponatraemia 116.53 21.09 156 14087 101306 42505786
Incorrect route of product administration 113.60 21.09 81 14162 24224 42582868
Bacterial infection 110.23 21.09 84 14159 27795 42579297
Renal failure 103.80 21.09 178 14065 143548 42463544
Dry mouth 103.19 21.09 94 14149 39785 42567307
Blood cholesterol increased 97.93 21.09 77 14166 26664 42580428
Ascites 90.61 21.09 103 14140 56575 42550517
Iron deficiency 86.62 21.09 51 14192 11010 42596082
Abdominal distension 81.83 21.09 110 14133 71625 42535467
Activated partial thromboplastin time prolonged 81.28 21.09 56 14187 15847 42591245
Anticoagulant therapy 79.60 21.09 36 14207 4499 42602593
Antacid therapy 78.24 21.09 36 14207 4681 42602411
Swelling 74.90 21.09 92 14151 54793 42552299
Diabetes mellitus 74.49 21.09 96 14147 59991 42547101
Blood calcium increased 74.24 21.09 42 14201 8412 42598680
Congenital hiatus hernia 71.91 21.09 37 14206 6137 42600955
Anxiety 70.44 21.09 135 14108 118425 42488667
Blood creatinine increased 70.01 21.09 129 14114 109874 42497218
Sleep disorder 67.86 21.09 82 14161 48013 42559079
Bronchopulmonary aspergillosis allergic 66.73 21.09 32 14211 4566 42602526
Intentional product misuse 64.67 21.09 91 14152 61809 42545283
Brain oedema 61.89 21.09 48 14195 16279 42590813
Somnolence 59.81 21.09 140 14103 140965 42466127
Condition aggravated 58.88 21.09 206 14037 260548 42346544
Ulcer 57.30 21.09 46 14197 16395 42590697
End stage renal disease 57.01 21.09 46 14197 16512 42590580
Thrombosis 56.26 21.09 90 14153 68421 42538671
Troponin increased 55.37 21.09 48 14195 19014 42588078
Blood test abnormal 53.45 21.09 40 14203 12866 42594226
Aortic stenosis 52.39 21.09 34 14209 8711 42598381
General physical health deterioration 51.43 21.09 138 14105 151108 42455984
Chronic obstructive pulmonary disease 50.57 21.09 82 14161 63032 42544060
Fall 50.06 21.09 9 14234 234511 42372581
Incision site pain 49.62 21.09 20 14223 1883 42605209
Pleuritic pain 48.61 21.09 30 14213 7047 42600045
Hyperlipidaemia 46.62 21.09 46 14197 21470 42585622
Blood urea increased 46.38 21.09 56 14187 32737 42574355
Pain 44.08 21.09 180 14063 244668 42362424
Sepsis 43.65 21.09 156 14087 199178 42407914
Hypercholesterolaemia 42.76 21.09 35 14208 12814 42594278
Red blood cells urine positive 42.76 21.09 18 14225 1892 42605200
Diarrhoea 42.72 21.09 55 14188 460794 42146298
Brain herniation 42.45 21.09 24 14219 4799 42602293
Procalcitonin decreased 42.14 21.09 11 14232 254 42606838
Eosinophil percentage decreased 41.65 21.09 11 14232 266 42606826
Blood creatine decreased 41.50 21.09 11 14232 270 42606822
Weight decreased 40.23 21.09 10 14233 207938 42399154
Drug intolerance 39.87 21.09 85 14158 80339 42526753
Gout 38.19 21.09 47 14196 28008 42579084
Drug hypersensitivity 38.19 21.09 95 14148 99294 42507798
Bacteroides infection 37.52 21.09 18 14225 2569 42604523
Breath sounds abnormal 36.23 21.09 31 14212 12062 42595030
Drug interaction 35.20 21.09 23 14220 266976 42340116
Total lung capacity decreased 34.80 21.09 19 14224 3551 42603541
Constipation 34.63 21.09 126 14117 162165 42444927
Micturition urgency 34.63 21.09 30 14213 11868 42595224
Arthralgia 34.07 21.09 13 14230 205225 42401867
Fear of death 32.87 21.09 11 14232 611 42606481
Pulmonary embolism 32.73 21.09 101 14142 119511 42487581
Aspiration 31.11 21.09 34 14209 17852 42589240
Respiratory symptom 30.31 21.09 27 14216 11079 42596013
Aortic valve calcification 29.89 21.09 10 14233 555 42606537
Cardiovascular disorder 29.74 21.09 29 14214 13336 42593756
Joint injury 29.26 21.09 30 14213 14646 42592446
Blood folate decreased 29.13 21.09 11 14232 870 42606222
Protein urine present 28.63 21.09 20 14223 5781 42601311
Abdominal pain 28.10 21.09 132 14111 190339 42416753
Blood urea decreased 27.36 21.09 12 14231 1394 42605698
Lymphocyte count decreased 26.26 21.09 39 14204 27770 42579322
Optic atrophy 25.41 21.09 11 14232 1238 42605854
Benign prostatic hyperplasia 25.06 21.09 33 14210 21019 42586073
Drug abuse 24.68 21.09 3 14240 104768 42502324
Lung opacity 23.96 21.09 18 14225 5819 42601273
Fatigue 23.80 21.09 71 14172 435570 42171522
Toxicity to various agents 23.68 21.09 25 14218 229111 42377981
COVID-19 23.55 21.09 5 14238 115943 42491149
Blood magnesium decreased 23.54 21.09 20 14223 7706 42599386
Propofol infusion syndrome 22.50 21.09 10 14233 1199 42605893
Toxic neuropathy 21.76 21.09 8 14235 587 42606505
Weight increased 21.24 21.09 5 14238 107978 42499114

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Renal injury 449.07 20.46 156 19392 18557 110551194
Fear 423.68 20.46 158 19390 23035 110546716
Stress 360.38 20.46 227 19321 105121 110464630
Renal impairment 346.70 20.46 278 19270 188167 110381584
Multiple organ dysfunction syndrome 340.70 20.46 252 19296 151458 110418293
Anhedonia 333.41 20.46 119 19429 15309 110554442
Unevaluable event 290.06 20.46 161 19387 59066 110510685
Emotional distress 281.93 20.46 144 19404 44703 110525048
Appendicolith 252.56 20.46 95 19453 14160 110555591
Renal failure 241.68 20.46 246 19302 226328 110343423
Blood phosphorus increased 219.17 20.46 89 19459 16251 110553500
Myasthenia gravis 217.98 20.46 96 19452 21415 110548336
Hyperphosphataemia 208.71 20.46 86 19462 16295 110553456
Appendicitis 195.27 20.46 97 19451 28367 110541384
Ventricular fibrillation 185.13 20.46 106 19442 41207 110528544
Hypophosphataemia 175.63 20.46 95 19453 33087 110536664
Injury 161.35 20.46 177 19371 177088 110392663
Hyponatraemia 158.97 20.46 194 19354 217459 110352292
Analgesic therapy 152.87 20.46 55 19493 7229 110562522
Blood uric acid increased 149.54 20.46 74 19474 21455 110548296
Cardiogenic shock 148.51 20.46 104 19444 57234 110512517
Sleep disorder therapy 147.78 20.46 54 19494 7417 110562334
Drug therapy 145.34 20.46 53 19495 7238 110562513
Blood creatinine increased 130.23 20.46 161 19387 182728 110387023
Neuralgia 125.70 20.46 88 19460 48390 110521361
Bacterial infection 122.71 20.46 85 19463 45951 110523800
Brain oedema 111.16 20.46 69 19479 31029 110538722
Ascites 110.27 20.46 107 19441 92701 110477050
Activated partial thromboplastin time prolonged 101.80 20.46 58 19490 22310 110547441
Incorrect route of product administration 97.80 20.46 85 19463 63976 110505775
Anticoagulant therapy 95.92 20.46 36 19512 5325 110564426
Antacid therapy 95.13 20.46 36 19512 5448 110564303
Anxiety 94.26 20.46 196 19352 344882 110224869
Congenital hiatus hernia 94.00 20.46 37 19511 6222 110563529
Iron deficiency 92.49 20.46 51 19497 18425 110551326
Diabetes mellitus 86.47 20.46 97 19451 99284 110470467
Arthralgia 83.54 20.46 18 19530 779614 109790137
Brain herniation 78.44 20.46 36 19512 8827 110560924
Sepsis 78.01 20.46 176 19372 327170 110242581
Thrombosis 77.83 20.46 96 19452 108566 110461185
Incision site pain 74.63 20.46 26 19522 3109 110566642
End stage renal disease 72.60 20.46 46 19502 21427 110548324
Abdominal distension 69.72 20.46 117 19431 174986 110394765
Bronchopulmonary aspergillosis allergic 67.67 20.46 32 19516 8394 110561357
Blood calcium increased 66.94 20.46 41 19507 17999 110551752
Somnolence 63.26 20.46 153 19395 297296 110272455
Troponin increased 59.04 20.46 46 19502 29720 110540031
Fall 58.66 20.46 17 19531 603465 109966286
Intentional product misuse 57.20 20.46 92 19456 132812 110436939
Maculopathy 56.61 20.46 21 19527 3006 110566745
Red blood cells urine positive 55.30 20.46 24 19524 5161 110564590
Chronic obstructive pulmonary disease 54.60 20.46 81 19467 109077 110460674
Blood urea increased 53.63 20.46 57 19491 54900 110514851
Hyperlipidaemia 53.56 20.46 47 19501 35801 110533950
Peripheral swelling 53.24 20.46 5 19543 404029 110165722
Blood test abnormal 52.07 20.46 42 19506 28512 110541239
Lymphocyte count decreased 51.71 20.46 57 19491 57186 110512565
Gout 50.78 20.46 46 19502 36520 110533231
Propofol infusion syndrome 48.56 20.46 18 19530 2571 110567180
Pulmonary embolism 47.38 20.46 112 19436 214362 110355389
Benign prostatic hyperplasia 47.01 20.46 33 19515 18201 110551550
Brain death 46.84 20.46 23 19525 6550 110563201
Bacteroides infection 46.46 20.46 18 19530 2901 110566850
Weight increased 46.30 20.46 9 19539 419635 110150116
Fatigue 46.12 20.46 91 19457 1215867 109353884
Protein urine present 44.92 20.46 27 19521 11457 110558294
Nasopharyngitis 44.49 20.46 8 19540 394353 110175398
Ulcer 44.35 20.46 46 19502 43070 110526681
Alopecia 44.32 20.46 6 19542 364747 110205004
Fear of death 44.25 20.46 15 19533 1652 110568099
Pleuritic pain 43.46 20.46 30 19518 16110 110553641
Condition aggravated 43.30 20.46 249 19299 734587 109835164
Cerebral haemorrhage 42.68 20.46 55 19493 64913 110504838
Rheumatoid arthritis 41.41 20.46 3 19545 299610 110270141
Weight decreased 40.56 20.46 16 19532 468041 110101710
Abdominal discomfort 40.31 20.46 10 19538 393848 110175903
Chest discomfort 39.71 20.46 92 19456 173756 110395995
Diarrhoea 39.24 20.46 90 19458 1139415 109430336
Micturition urgency 38.62 20.46 30 19518 19290 110550461
Respiratory symptom 38.42 20.46 27 19521 14918 110554833
CSF volume decreased 38.21 20.46 5 19543 0 110569751
Dry mouth 37.39 20.46 98 19450 199850 110369901
Sinusitis 35.75 20.46 5 19543 296683 110273068
Breath sounds abnormal 35.35 20.46 32 19516 25372 110544379
Constipation 34.65 20.46 140 19408 357646 110212105
Aspiration 34.00 20.46 34 19514 30499 110539252
Neutrophil count increased 33.91 20.46 36 19512 34616 110535135
Total lung capacity decreased 33.86 20.46 19 19529 7095 110562656
Product use issue 33.71 20.46 7 19541 311688 110258063
Rash erythematous 32.97 20.46 55 19493 81777 110487974
Intentional product use issue 32.82 20.46 3 19545 247903 110321848
Hypokalaemia 32.67 20.46 88 19460 182360 110387391
Cardiovascular disorder 32.32 20.46 29 19519 22731 110547020
Hyperkalaemia 32.26 20.46 73 19475 135723 110434028
Therapeutic product effect decreased 32.23 20.46 3 19545 244313 110325438
Aortic stenosis 32.20 20.46 23 19525 13036 110556715
Infusion related reaction 31.45 20.46 14 19534 381148 110188603
Mobility decreased 31.09 20.46 3 19545 237419 110332332
Tick-borne viral encephalitis 30.52 20.46 7 19541 180 110569571
Pain in extremity 30.28 20.46 25 19523 487093 110082658
Chills 30.26 20.46 88 19460 190492 110379259
Confusional state 29.20 20.46 24 19524 468656 110101095
Coma 28.71 20.46 64 19484 117805 110451946
Malaise 28.32 20.46 47 19501 671772 109897979
Intracranial pressure increased 27.00 20.46 19 19529 10516 110559235
Anaemia 26.87 20.46 177 19371 546909 110022842
Transaminases increased 26.06 20.46 43 19505 63347 110506404
General physical health deterioration 25.55 20.46 145 19403 425150 110144601
Complications of transplanted kidney 25.30 20.46 16 19532 7426 110562325
Treatment failure 24.79 20.46 9 19539 277225 110292526
Spinal cord injury cervical 24.75 20.46 6 19542 197 110569554
Optic atrophy 24.72 20.46 11 19537 2510 110567241
Inflammation 23.89 20.46 3 19545 193235 110376516
COVID-19 23.59 20.46 7 19541 245053 110324698
Sleep disorder 23.58 20.46 83 19465 198561 110371190
Blood cholesterol increased 23.49 20.46 79 19469 184706 110385045
Hepatic function abnormal 23.47 20.46 50 19498 89245 110480506
Temperature intolerance 22.27 20.46 19 19529 13931 110555820
Psychological trauma 22.04 20.46 9 19539 1664 110568087
Toxic neuropathy 21.77 20.46 8 19540 1115 110568636
Drug abuse 21.34 20.46 3 19545 177408 110392343
Fanconi syndrome 21.22 20.46 11 19537 3508 110566243
Lung opacity 20.95 20.46 17 19531 11635 110558116
Chemical burn 20.92 20.46 7 19541 741 110569010
Hyperosmolar state 20.72 20.46 7 19541 763 110568988
Toxic optic neuropathy 20.47 20.46 8 19540 1320 110568431
Therapeutic product effect incomplete 20.46 20.46 7 19541 223798 110345953

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A06AD16 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR CONSTIPATION
DRUGS FOR CONSTIPATION
Osmotically acting laxatives
ATC B05BC01 BLOOD AND BLOOD FORMING ORGANS
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
I.V. SOLUTIONS
Solutions producing osmotic diuresis
ATC B05CX04 BLOOD AND BLOOD FORMING ORGANS
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
IRRIGATING SOLUTIONS
Other irrigating solutions
ATC R05CB16 RESPIRATORY SYSTEM
COUGH AND COLD PREPARATIONS
EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS
Mucolytics
ATC V04CX04 VARIOUS
DIAGNOSTIC AGENTS
OTHER DIAGNOSTIC AGENTS
Other diagnostic agents
FDA MoA N0000010288 Osmotic Activity
FDA PE N0000175359 Increased Diuresis
MeSH PA D004232 Diuretics
MeSH PA D004234 Diuretics, Osmotic
MeSH PA D005421 Flavoring Agents
MeSH PA D005503 Food Additives
MeSH PA D013549 Sweetening Agents
MeSH PA D045283 Natriuretic Agents
FDA EPC N0000175810 Osmotic Diuretic
CHEBI has role CHEBI:23366 compatible osmolytes
CHEBI has role CHEBI:25212 metabolite
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:50504 osmotic diuretic
CHEBI has role CHEBI:50505 sweetening agent
CHEBI has role CHEBI:50904 allergen
CHEBI has role CHEBI:59174 hapten
CHEBI has role CHEBI:76971 <em>Escherichia coli</em> metabolite
CHEBI has role CHEBI:77965 food anticaking agent
CHEBI has role CHEBI:77966 food stabiliser
CHEBI has role CHEBI:77969 food humectant
CHEBI has role CHEBI:77970 food thickening agent
CHEBI has role CHEBI:78004 food bulking agent
CHEBI has role CHEBI:75772 <em>Saccharomyces cerevisiae </em> metabolite
CHEBI has role CHEBI:76924 plant metabolite
CHEBI has role CHEBI:77746 human metabolite

Related Drugs by ATC class:

A06AD Osmotically acting laxatives 13 drugs
lactitollactulosemacrogolmagnesium carbonatemagnesium citratemagnesium oxidemagnesium peroxidemagnesium sulfatepentaerythritolsodium phosphatesodium sulfatesodium tartrate show all 13 →
B05BC Solutions producing osmotic diuresis 1 drug
carbamide
B05CX Other irrigating solutions 3 drugs
glucoseglycinesorbitol
R05CB Mucolytics 13 drugs
acetylcysteineambroxolbromhexinecarbocisteinedomiodoldornase alfaeprazinoneerdosteineletosteinemesnaneltenexinesobrerol show all 13 →
V04CX Other diagnostic agents 9 drugs
5-aminolevulinic acid hexyl esteredrophoniumfolic acidindocyanine greenmethacholinepafolacianinepegulicianineUREA C-13xenon

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Cerebral edema indication 2032001
Ocular hypertension indication 4210003 DOID:9282
Benign intracranial hypertension indication 68267002 DOID:11459
Cystic fibrosis indication 190905008 DOID:1485
Edema indication 267038008
Hemolysis Prevention indication
Intracranial hemorrhage contraindication 1386000
Anuria contraindication 2472002 DOID:2983
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Hepatic encephalopathy contraindication 13920009 DOID:13413
Hyperkalemia contraindication 14140009
Hypovolemia contraindication 28560003
Depressive disorder contraindication 35489007
Hypernatremia contraindication 39355002
Chronic heart failure contraindication 48447003
Hepatic failure contraindication 59927004
Poisoning by phenobarbital contraindication 64921004
Substance abuse contraindication 66214007
Pulmonary congestion contraindication 67599009
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Oliguria contraindication 83128009
Hyponatremia contraindication 89627008
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Fragile capillaries contraindication 248726001
Dyspnea contraindication 267036007
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Breastfeeding (mother) contraindication 413712001
Porphyria contraindication 418470004
Severe dehydration contraindication 450316000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.21 acidic
pKa2 13.75 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
40MG BRONCHITOL PHARMAXIS EUROPE N202049 Oct. 30, 2020 RX POWDER INHALATION Oct. 30, 2027 ADD-ON MAINTENANCE THERAPY TO IMPROVE PULMONARY FUNCTION IN ADULT PATIENTS 18 YEARS OF AGE AND OLDER WITH CYSTIC FIBROSIS AND WHO HAVE PASSED THE BRONCHITOL TOLERANCE TEST

Bioactivity Summary:

None

External reference:

IDSource
4017741 VUID
N0000146108 NUI
D00062 KEGG_DRUG
2475836 RXNORM
4017741 VANDF
C0024730 UMLSCUI
CHEBI:16899 CHEBI
MTL PDB_CHEM_ID
CHEMBL689 ChEMBL_ID
D008353 MESH_DESCRIPTOR_UI
DB00742 DRUGBANK_ID
3OWL53L36A UNII
6251 PUBCHEM_CID
189996 MMSL
5022 MMSL
7928 MMSL
d00282 MMSL
002272 NDDF
004521 NDDF
30761007 SNOMEDCT_US
387168006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Mannitol HUMAN PRESCRIPTION DRUG LABEL 1 0264-7578 INJECTION, SOLUTION 20 g INTRAVENOUS NDA 22 sections
Osmitrol HUMAN PRESCRIPTION DRUG LABEL 1 0338-0353 INJECTION, SOLUTION 10 g INTRAVENOUS NDA 23 sections
Osmitrol HUMAN PRESCRIPTION DRUG LABEL 1 0338-0357 INJECTION, SOLUTION 20 g INTRAVENOUS NDA 23 sections
Mannitol HUMAN PRESCRIPTION DRUG LABEL 1 0404-9905 INJECTION, SOLUTION 12.50 g INTRAVENOUS NDA 16 sections
Mannitol HUMAN PRESCRIPTION DRUG LABEL 1 0409-4031 INJECTION, SOLUTION 12.50 g INTRAVENOUS NDA 24 sections
Mannitol HUMAN PRESCRIPTION DRUG LABEL 1 0990-7715 INJECTION, SOLUTION 20 g INTRAVENOUS NDA 24 sections
Mannitol HUMAN PRESCRIPTION DRUG LABEL 1 0990-7715 INJECTION, SOLUTION 20 g INTRAVENOUS NDA 24 sections
Sorbitol-Mannitol HUMAN PRESCRIPTION DRUG LABEL 2 0990-7981 IRRIGANT 0.54 g URETHRAL NDA 12 sections
Sorbitol-Mannitol HUMAN PRESCRIPTION DRUG LABEL 2 0990-7981 IRRIGANT 0.54 g URETHRAL NDA 12 sections
MANNITOL HUMAN PRESCRIPTION DRUG LABEL 1 51662-1468 INJECTION, SOLUTION 12.50 g INTRAVENOUS NDA 17 sections
GD11 Rx SCM C5 HUMAN OTC DRUG LABEL 1 62171-100 LIQUID 0.10 g TOPICAL unapproved drug other 8 sections
Mannitol HUMAN PRESCRIPTION DRUG LABEL 1 63323-024 INJECTION, SOLUTION 250 mg INTRAVENOUS ANDA 11 sections
QR PAIN HUMAN OTC DRUG LABEL 2 73180-005 CREAM 30 g TOPICAL OTC Monograph Drug 12 sections
QR PAIN HUMAN OTC DRUG LABEL 2 73180-075 CREAM 30 g TOPICAL OTC Monograph Drug 12 sections
CURESTEM CELL HEALER C20 HUMAN OTC DRUG LABEL 1 78521-020 POWDER 0.06 g TOPICAL unapproved drug other 12 sections
Mannitol HUMAN PRESCRIPTION DRUG LABEL 1 84549-024 INJECTION, SOLUTION 250 mg INTRAVENOUS ANDA 10 sections
BRONCHITOL HUMAN PRESCRIPTION DRUG LABEL 1 84639-212 CAPSULE 40 mg RESPIRATORY (INHALATION) NDA 18 sections